[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@EiocOncology Excellence in Oncology Care - EIOC
Excellence in Oncology Care - EIOC posts on X about matterhorn, breast cancer, dubai, united arab emirates the most. They currently have XXX followers and XX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Month XXXXX +665%
- X Months XXXXX +1,701%
- X Year XXXXX +791%
Mentions: X #
Followers: XXX #
- X Month XXX +5.50%
- X Months XXX +15%
- X Year XXX +28%
CreatorRank: undefined #
Social Influence #
Social category influence travel destinations XXXXX% countries XXXX% stocks XXXX% currencies XXXX%
Social topic influence matterhorn 12.5%, breast cancer 6.25%, dubai 6.25%, united arab emirates 6.25%, ctx 6.25%, kuwait 6.25%, checkpoint XXXX%
Top accounts mentioned or mentioned by @oncoalert @lillypad
Top Social Posts #
Top posts by engagements in the last XX hours
"Matterhorn associated with an os advantage Adding durva improves os across pdl1 subgroups #ESMO2025 #ESMO25 #CANCERRESEARCH #ONCOLOGY #YOUNGONCOLOGISTS #MATTERHIRN #ONCOLOGYCONFERENCE"
X Link @EiocOncology 2025-10-17T08:11Z XXX followers, XXX engagements
"👉MATTERHORN: Phase III study of durvalumab + FLOT in resectable G / GEJ adenocarcinoma 👉 pCR: XX% MPR: XX% 👉 OS: HR: 0.78; 36-mo OS: XX vs XX% 👉os improved independent of pdl1 👉new standard of care #ESMO25 #CANCERRESEARCH #ONCOLOGY #YOUNGONCOLOGISTS #ONCOLOGYCONFERENCE"
X Link @EiocOncology 2025-10-17T15:29Z XXX followers, XX engagements
"👉Ascent XX now out in #NEJM 👉Sacituzumab govitecan led to significantly longer progression-free survival than chemotherapy among patients with advanced triple-negative breast cancer who were not candidates for treatment with PD-1 or PD-L1 inhibitors. #ESMO25 #ESMO2025 #NEJM"
X Link @EiocOncology 2025-10-19T07:35Z XXX followers, XXX engagements
"👉out in the lancet 👉STELLAR-303 👉phase X trial 👉 improvement in overall survival zanzalintinibatezolizumab in patients with relapsed or refractory metastatic colorectal cancer that is not MSI-H or dMMR #ESMO25 #ESMO2025 #ONCOLOGYNEWS #ONCOLOGYRESEARCH #MEDICALCONFERENCE"
X Link @EiocOncology 2025-10-20T19:34Z XXX followers, XXX engagements
"Proud to welcome Bristol Myers Squibb as a Gold Sponsor at #EIOC2025 taking place XX Oct2 Nov 2025 at InterContinental Festival City Dubai United Arab Emirates. Complimentary registration for healthcare professionals: #Oncology #BMS #MedicalEducation"
X Link @EiocOncology 2025-10-17T07:12Z XXX followers, XX engagements
"Sara Hurwitz presents results of Vitoria X. Lessons learnt: X. Combination therapy matters in the hr pos disease X. there is a role for cdk4/6i beyond progression of disease #ESMO25 #ESMO2025 #ONCOLOGYNEWS @OncoAlert #ONCOLOGYRESEARCH #MEDICALCONFERENCE #ONCOALERT #ASCO #EIOC"
X Link @EiocOncology 2025-10-18T11:07Z XXX followers, XXX engagements
"(1/2) 👉DYNAMIC-III trial 👉ctDNA-guided adjuvant CTx de-escalation in stage III CRC 👉analysis of the ctDNA-cohort 👉 reduced oxaliplatin exposure 👉 non-inferiority not demonstrated"
X Link @EiocOncology 2025-10-20T18:37Z XXX followers, XX engagements
"Join us on X Nov 2025 at EIOC 2025 as Dr. Ammar Madani from NCCCR Kuwait discusses Evolution of Checkpoint Inhibitors in rNSCLC. 🔗 #EIOC2025 #LungCancer #NSCLC #Immunotherapy"
X Link @EiocOncology 2025-10-22T13:25Z XXX followers, XX engagements